New Delhi, March 2 Emcure Pharmaceuticals announced on Monday that it has signed a distribution agreement with Roche for select products in the nephrology and transplant medicine portfolio.
Under the agreement, which takes effect on April 1, 2026, Emcure will distribute Roche's established and globally recognized brands in the nephrology and transplant segment in India, Emcure Pharmaceuticals said in a regulatory filing.
The agreement includes brands such as 'CellCept' – a globally leading immunosuppressant and original Roche innovation, which has supported organ transplants worldwide since 1995, along with 'Mircera' and 'Neorecormon', which are proven therapies for anemia in chronic kidney disease (CKD).
"Roche's globally trusted innovations strongly complement our existing portfolio and reach. Together, we aim to expand access to these critical therapies and support physicians in delivering optimal care to patients across India," said Satish Mehta, Managing Director & CEO of Emcure Pharmaceuticals.
Rajji Mehdwan, Managing Director & CEO of Roche India & Neighbouring Markets, said, "Through Emcure's strong distribution network and clinical engagement, we believe these medicines can reach a larger number of patients who can benefit from Roche's long-standing innovations in transplant and CKD care."
The collaboration is aimed at improving patient access to proven therapies while supporting better anemia management and long-term outcomes for patients with CKD and transplant needs, the company said.